Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy

This study has been terminated.
(Inadequate enrollment)
National Cancer Institute (NCI)
AMAG Pharmaceuticals, Inc.
Information provided by (Responsible Party):
OHSU Knight Cancer Institute Identifier:
First received: October 7, 2008
Last updated: November 17, 2014
Last verified: November 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)